Drugs / A-002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00525954 | Sep → Dec 2007 | coronary artery disorder | Anthera Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | A-002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00525954 ↗ |
| Action | Inhibit | “novel sPLA(2) inhibitor” PMID 21081550 ↗ Nov 2010 |
| Route | Oral | “orally active doses of A-002” NCT00525954 ↗ |